Skip to main content

Saxenda® (liraglutide) injection

Saxenda® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia).

Search for Letters

Find documents for this product by entering your search terms in the box below.

 

Text: double click to edit.

Have a Question?

Request information directly from the Novo Nordisk
Medical Information department.